U.S. Markets open in 5 hrs 25 mins

Incyte Advances R&D Strategy with Multiple Partnerships

Margaret Patrick
Incyte Advances R&D Strategy with Multiple Partnerships

In January 2015, Incyte (INCY) entered an antibody discovery collaboration with Agenus (AGEN), which was later amended in February 2017. As per the amended agreement, the ongoing research programs for the development of checkpoint modulator antibodies targeted at GITR and OX40 have been converted from co-funded ones to being fully funded by Incyte. Additionally, the profit-sharing arrangement for these research programs has been converted into royalty-bearing programs.